Another study of adult PWH compared INSTI (raltegravir and dolutegravir), protease inhibitor (darunavir) and NNRTI (rilpivirine) and found all ART, except rilpivirine, had a significant increase in BMI at 1 year and adjustment for multiple confounders (age, sex, CD4 count, CDC stage, HIV viral load, presence of lipodystrophy/lipoatrophy, ART duration < or ≥ 3 years, and initial BMI class) diminished differences between the ART [21]. This evidence concerns the gene CD4 and lipodystrophy.